Bonenkamp J J, Sasako M, Hermans J, van de Velde C J
University Medical Center, St Radboud Nijmegen, The Netherlands.
Hepatogastroenterology. 2001 Sep-Oct;48(41):1219-21.
BACKGROUND/AIMS: Most patients with gastric cancer will have resection, even if their disease stage is beyond curability. Proper criteria to assess tumor load in patients deemed noncurative are lacking, and therefore, it is not clear which of these patients will benefit from resection.
Of 996 gastric cancer patients who had laparotomy in a national randomized trial of lymphadenectomy for gastric cancer, 285 (29%) were found to be noncurable because of remnant tumor, peritoneal metastases, distant lymph node metastases or liver metastases. They underwent a palliative procedure considered appropriate by the surgeon. Tumor load in this group was analyzed retrospectively by calculating the number of noncurability signs.
The number of signs of noncurability was related to the type of surgical palliation chosen by the surgeon: of those patients with only one sign of noncurability, 68% had a palliative stomach resection but, of patients with two or more positive signs of noncurability only 36% had a stomach resection. Median survival after palliative resection was 253 days compared to 169 days after a nonresective procedure (P = 0.002). This survival advantage for resected patients disappeared when two or more signs of noncurability were found.
For patients deemed noncurative, survival depends on tumor load. Accurate preoperative assessment of tumor spread may prevent unnecessary high-risk surgical interventions for patients with noncurative gastric cancer.
背景/目的:大多数胃癌患者即便疾病分期已无法治愈,仍会接受手术切除。目前缺乏评估不可治愈患者肿瘤负荷的恰当标准,因此,尚不清楚这些患者中哪些能从手术切除中获益。
在一项全国性胃癌淋巴结清扫随机试验中,996例行剖腹手术的胃癌患者中,有285例(29%)因残留肿瘤、腹膜转移、远处淋巴结转移或肝转移而被判定为不可治愈。他们接受了外科医生认为合适的姑息性手术。通过计算不可治愈体征的数量,对该组患者的肿瘤负荷进行回顾性分析。
不可治愈体征的数量与外科医生选择的姑息性手术类型有关:仅有一个不可治愈体征的患者中,68%接受了姑息性胃切除术,但有两个或更多不可治愈阳性体征的患者中,只有36%接受了胃切除术。姑息性切除术后的中位生存期为253天,而非切除术后为169天(P = 0.002)。当发现两个或更多不可治愈体征时,切除患者的这种生存优势消失。
对于判定为不可治愈的患者,生存取决于肿瘤负荷。准确的术前肿瘤扩散评估可避免对不可治愈胃癌患者进行不必要的高风险手术干预。